Seed Round Now Open

Prescription-grade hearing technology for the 1.57 billion people left behind

Prescription-grade hearing technology for the 1.57 billion people left behind

Hear for Everyone.

Sonotu is commercialising a proprietary platform built on reconfigurable ultra-low-power

silicon and HeartuAI™ edge AI to deliver prescription-grade hearing performance at a fraction of traditional chipset costs.

This page is intended for qualifying investors only. Investment in early-stage companies carries significant risk, including loss of capital.

Six Independent Proof Points

Every material claim Sonotu makes about its technology has been validated by an independent third party — clinical, regulatory, algorithmic, and manufacturing.

01 · Institutional

University of Warwick Spin-Out, independently assessed and endorsed for commercial viability.

02 · Clinical

Green Pastures Hospital evaluated Gen1 under real clinical conditions in Pokhara, Nepal.

03 · Technical

ManCAD at the University of Manchester validated core signal processing performance against IEC and ANSI benchmarks.

04 · Manufacturing

Devices are manufactured by RVM in Chennai under ISO 13485:2016 medical device quality certification.

05 · Regulatory

Commercially launched and distributing nationally in India with certified Gen1 product foundations.

06 · Platform

HeartuAI™ and RULPS create a fundamentally different hearing architecture for emerging markets.

Register Your Interest

To receive the Investment Memorandum, self-certify as a qualifying investor. A member of the team will respond within two business days.



Prescription grade hearing technology for the 1.57 billion people left behind

This page is intended for qualifying investors only. Investment in early-stage companies carries significant risk, including loss of capital.

Seed Round Now Open